

**Amendments to the Claims:**

The following listing of claims replaces all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A method of treating or inhibiting obesity in a patient, comprising identifying a compound which inhibits de novo lipogenesis in a mammal, wherein said compound is identified by measuring ~~the effect of~~ whether at least one candidate compound has an effect on ~~[[the]]~~ carboanhydrase activity in a mammal, and selecting a compound which inhibits activity of at least one mammalian carboanhydrase, and administering an effective obesity inhibiting amount of ~~[[said]]~~ the selected compound to said patient, with the proviso that ~~[[said]]~~ the selected compound is not topiramate.

2. (canceled)

3. (previously presented) A method according to claim 1, wherein said compound inhibits activity of at least one mammalian carboanhydrase in an *in vitro* enzyme activity test, and reduces an amount of metabolic products formed in the citric acid cycle of isolated living mammalian cells.

4. (original) A method according to claim 1, wherein said compound is administered to the patient over a period of at least six weeks.

5-6. (canceled)